share_log

Victory Capital Management Inc. Raises Stock Position in Enovis Co. (NYSE:ENOV)

Victory Capital Management Inc. Raises Stock Position in Enovis Co. (NYSE:ENOV)

勝利資本管理公司提高了 ENOVIS 公司的股票頭寸（紐約：能諾夫）
Defense World ·  2023/01/25 06:11

Victory Capital Management Inc. lifted its position in Enovis Co. (NYSE:ENOV – Get Rating) by 0.6% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 416,342 shares of the company's stock after buying an additional 2,360 shares during the period. Victory Capital Management Inc. owned approximately 0.77% of Enovis worth $19,181,000 as of its most recent SEC filing.

勝利資本管理公司在最近提交給美國證券交易委員會的文件中説，該公司在第三季度將其在Enovis Co.(NYSE：ENOV-GET評級)的持倉提高了0.6%。該基金持有該公司416,342股股票，在此期間又購買了2,360股。截至最近提交給美國證券交易委員會的文件，勝利資本管理公司持有Enovis約0.77%的股份，價值19,181,000美元。

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Wipfli Financial Advisors LLC purchased a new stake in Enovis during the 3rd quarter worth approximately $36,000. M&T Bank Corp purchased a new stake in Enovis during the 2nd quarter worth approximately $137,000. Paloma Partners Management Co purchased a new stake in shares of Enovis in the 2nd quarter valued at $209,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Enovis in the 2nd quarter valued at $261,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Enovis in the 2nd quarter valued at $285,000. Hedge funds and other institutional investors own 96.73% of the company's stock.

其他一些機構投資者和對衝基金最近也調整了對該公司的持股。Wipfli Financial Advisors LLC在第三季度購買了Enovis的新股份，價值約3.6萬美元。M&T Bank Corp在第二季度購買了Enovis的新股份，價值約13.7萬美元。Paloma Partners Management Co在第二季度購買了價值20.9萬美元的Enovis新股。康納·克拉克和倫恩投資管理有限公司在第二季度購買了價值261,000美元的Enovis新股。最後，Zurcher Kantonalbank蘇黎世廣東銀行在第二季度購買了價值28.5萬美元的Enovis新股。對衝基金和其他機構投資者持有該公司96.73%的股票。

Get
到達
Enovis
伊諾維斯
alerts:
警報：

Analyst Upgrades and Downgrades

分析師升級和下調評級

Several analysts have recently commented on ENOV shares. Evercore ISI upped their price objective on shares of Enovis to $68.00 in a report on Tuesday, January 3rd. The Goldman Sachs Group initiated coverage on shares of Enovis in a research report on Tuesday, October 11th. They set a "buy" rating and a $57.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Enovis in a report on Wednesday, October 12th. They set a "buy" rating and a $60.00 target price for the company. Robert W. Baird dropped their target price on shares of Enovis from $73.00 to $68.00 and set an "outperform" rating for the company in a report on Thursday, November 3rd. Finally, TheStreet lowered shares of Enovis from a "c" rating to a "d" rating in a report on Wednesday, November 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $63.50.

幾位分析師最近對ENOV的股票發表了評論。在1月3日星期二的一份報告中，Evercore ISI將Enovis的股價目標上調至68.00美元。10月11日，星期二，高盛在一份研究報告中首次對依諾維斯的股票進行了報道。他們為該公司設定了“買入”評級和57.00美元的目標價。傑富瑞金融集團在10月12日星期三的一份報告中啟動了對Enovis股票的報道。他們為該公司設定了“買入”評級和60.00美元的目標價。羅伯特·W·貝爾德在11月3日星期四的一份報告中將Enovis的股票目標價從73.00美元下調至68.00美元，併為該公司設定了“跑贏大盤”的評級。最後，華爾街在11月2日星期三的一份報告中將Enovis的股票評級從C級下調至D級。兩名研究分析師對該股的評級為持有，七名分析師對該股的評級為買入。根據MarketBeat的數據，該股目前的共識評級為“適度買入”，共識目標價為63.50美元。

Insider Transactions at Enovis

Enovis的內幕交易

In related news, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $55.28, for a total value of $75,567.76. Following the completion of the transaction, the chief financial officer now owns 44,605 shares of the company's stock, valued at approximately $2,465,764.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at
在相關新聞中，首席財務官克里斯托弗·M·希克斯在12月14日星期三的一筆交易中出售了1,367股該公司的股票。這些股票的平均價格為55.28美元，總價值為75,567.76美元。交易完成後，首席財務官現在擁有該公司44,605股股票，價值約2,465,764.40美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可在
the SEC website
美國證券交易委員會網站
. In other Enovis news, EVP Daniel A. Pryor sold 67,421 shares of Enovis stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $54.58, for a total value of $3,679,838.18. Following the completion of the sale, the executive vice president now owns 75,731 shares in the company, valued at approximately $4,133,397.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through
。在Enovis的其他消息中，執行副總裁Daniel·A·普賴爾在11月15日星期二的交易中出售了67,421股Enovis股票。這隻股票的平均售價為54.58美元，總價值為3,679,838.18美元。出售完成後，執行副總裁總裁現在擁有該公司75,731股股份，價值約4,133,397.98美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，可以通過以下方式獲取
this link
這個環節
. Also, CFO Christopher M. Hix sold 1,367 shares of the business's stock in a transaction dated Wednesday, December 14th. The stock was sold at an average price of $55.28, for a total value of $75,567.76. Following the sale, the chief financial officer now owns 44,605 shares of the company's stock, valued at approximately $2,465,764.40. The disclosure for this sale can be found
。此外，首席財務官克里斯托弗·M·希克斯在日期為12月14日(星期三)的交易中出售了1,367股該公司股票。這隻股票的平均售價為55.28美元，總價值為75567.76美元。出售後，首席財務官現在擁有44,605股公司股票，價值約2,465,764.40美元。關於這次銷售的披露可以找到
here
這裏
. Corporate insiders own 8.30% of the company's stock.
。公司內部人士持有該公司8.30%的股份。

Enovis Trading Down 0.7 %

Enovis股價下跌0.7%

ENOV stock opened at $60.54 on Wednesday. The stock has a market cap of $3.28 billion, a P/E ratio of 126.13 and a beta of 1.99. The company's 50 day moving average is $55.55 and its two-hundred day moving average is $53.44. Enovis Co. has a twelve month low of $43.88 and a twelve month high of $129.70.

週三，ENOV的股票開盤報60.54美元。該股市值為32.8億美元，市盈率為126.13，貝塔係數為1.99%。該公司50日移動均線切入位在55.55美元，200日移動均線切入位在53.44美元。Enovis Co.股價跌至43.88美元的12個月低點，以及129.70美元的12個月高點。

Enovis (NYSE:ENOV – Get Rating) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.59 earnings per share for the quarter, beating analysts' consensus estimates of $0.47 by $0.12. Enovis had a net margin of 0.94% and a return on equity of 4.46%. The firm had revenue of $383.81 million for the quarter, compared to analyst estimates of $379.75 million. On average, equities research analysts predict that Enovis Co. will post 2.24 earnings per share for the current year.

Enovis(紐約證券交易所代碼：ENOV-GET Rating)最近一次公佈季度收益數據是在11月2日星期三。該公司公佈本季度每股收益為0.59美元，比分析師普遍預期的0.47美元高出0.12美元。Enovis的淨利潤率為0.94%，股本回報率為4.46%。該公司本季度營收為3.8381億美元，而分析師預期為3.7975億美元。股票研究分析師平均預測，Enovis Co.本年度每股收益將達到2.24歐元。

Enovis Company Profile

Enovis公司簡介

(Get Rating)

(獲取評級)

Enovis Corporation operates as a medical technology company worldwide. It develops, manufactures, and distributes medical device products used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports related injuries.

Enovis公司是一家全球性的醫療技術公司。該公司開發、製造和分銷醫療器械產品，供整形外科專家、外科醫生、初級保健醫生、疼痛管理專家、物理治療師、足科醫生、脊椎按摩師、運動訓練師和其他醫療保健專業人員使用，以治療因退行性疾病、畸形、創傷事件和運動相關傷害而導致的肌肉骨骼疾病患者。

Featured Articles

專題文章

  • Get a free copy of the StockNews.com research report on Enovis (ENOV)
  • Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
  • How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
  • Is the Pain Over for Baudax Bio Investors after a 70% Spike?
  • Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
  • Is It Time To Get Aggressive With Defense Stocks?
  • 免費獲取StockNews.com關於Enovis的研究報告(ENOV)
  • 柔順治療公司的差距增加了34%：未來還會有更多的好處嗎？
  • 2023年初裁員將如何影響這5只生物科技股？
  • Baudax Bio投資者在經歷了70%的飆升後，痛苦是否已經結束？
  • 火箭實驗室的首次美國發射將把斯托克送入平流層嗎？
  • 現在是時候積極投資國防類股了嗎？

Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.

接受《Enovis Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Enovis和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論